Focus Partners Wealth Acquires New Stake in Altimmune, Inc. (NASDAQ:ALT)

Focus Partners Wealth acquired a new stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 122,539 shares of the company's stock, valued at approximately $884,000. Focus Partners Wealth owned approximately 0.17% of Altimmune at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in shares of Altimmune in the fourth quarter valued at about $45,000. Virtus ETF Advisers LLC bought a new stake in shares of Altimmune in the fourth quarter valued at about $60,000. Cullen Frost Bankers Inc. bought a new position in Altimmune in the fourth quarter worth about $72,000. KLP Kapitalforvaltning AS bought a new position in Altimmune in the fourth quarter worth about $81,000. Finally, Raymond James Financial Inc. bought a new position in Altimmune in the fourth quarter worth about $88,000. 78.05% of the stock is currently owned by institutional investors.

Altimmune Trading Down 1.0%

Shares of ALT stock traded down $0.06 during trading hours on Friday, reaching $5.71. 1,651,677 shares of the company's stock were exchanged, compared to its average volume of 2,823,093. The stock's fifty day moving average price is $5.11 and its two-hundred day moving average price is $6.52. The stock has a market cap of $463.12 million, a PE ratio of -3.68 and a beta of 1.13. Altimmune, Inc. has a 1 year low of $3.55 and a 1 year high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. On average, equities analysts expect that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on ALT. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Finally, Wall Street Zen upgraded shares of Altimmune from a "sell" rating to a "hold" rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $20.20.

Insider Buying and Selling at Altimmune

In other Altimmune news, CFO Gregory L. Weaver bought 10,000 shares of Altimmune stock in a transaction dated Thursday, March 13th. The stock was acquired at an average cost of $5.20 per share, with a total value of $52,000.00. Following the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 4.10% of the stock is currently owned by corporate insiders.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.